Vaxart (STU:NB11) Inventories, Work In Process: €0.0 Mil (As of Mar. 2026)


STU:NB11 Vaxart Inc STU:NB11
59 GF Score
Price €0.60
GF Value €8.37
! 2 Warning Signs
View Full Analysis

What is Vaxart Inventories, Work In Process?

Vaxart STU:NB11 59 Inventories, Work In Process is €0.0 Mil as of Mar. 2026. GuruFocus rates STU:NB11 with a GF Score™ of 59/100 and a GF Value™ of €8.37. The stock has 2 warning signs investors should review.

Work in process is the part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. Vaxart's work in process for the quarter that ended in Mar. 2026 was €0.0 Mil.

Vaxart Inventories, Work In Process Historical Data

* Premium members only.

The historical data trend for Vaxart's Inventories, Work In Process can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vaxart Inventories, Work In Process Chart

Vaxart Annual Data
Trend Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Work In Process
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Vaxart Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Work In Process Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:NB11
59GF Score
Vaxart Inc STU:NB11
Inventories, Work In Process is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vaxart Inventories, Work In Process Calculation

That part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. This account contains the cost of the direct material, direct labor, and factory overhead placed into the products on the factory floor. A manufacturer must disclose in its financial statements the cost of its work-in-process as well as the cost of finished goods and materials on hand.

What does a Inventories, Work In Process of €0.0 Mil mean?
Vaxart (STU:NB11) has a Inventories, Work In Process of €0.0 Mil as of Mar. 2026. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on Vaxart and its competitors.
Is Vaxart's Inventories, Work In Process too high?
Vaxart's current Inventories, Work In Process is €0.0 Mil. Overall, Vaxart has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does Vaxart's Inventories, Work In Process compare to SPRO and ADCT?
Vaxart's Inventories, Work In Process of €0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Work In Process for a Biotechnology company?
A good Inventories, Work In Process depends on the Biotechnology industry context. However, Inventories, Work In Process should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Work In Process mean?
A high Inventories, Work In Process can signal that a stock is expensive relative to its fundamentals. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on Vaxart and its competitors. Vaxart's current Inventories, Work In Process is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaxart stock overvalued right now?
Vaxart (STU:NB11) has a current Inventories, Work In Process of €0.0 Mil. The stock's GF Value™ is €8.37, compared to a current price of €0.60 — trading 92.8% below its estimated fair value. The current Inventories, Work In Process is €0.0 Mil. Vaxart's overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Work In Process calculated?
Inventories, Work In Process is calculated from a company's financial statements. For Vaxart (STU:NB11), the current Inventories, Work In Process is €0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vaxart (STU:NB11) Overvalued in 2026?

Based on GuruFocus' analysis, Vaxart stock appears to be undervalued. The current stock price of €0.60 is trading 92.8% below its estimated GF Value™ of €8.37.

Key valuation signals for STU:NB11:

  • Inventories, Work In Process: €0.0 Mil
  • GF Value™: €8.37 vs. price of €0.60 (92.8% below fair value)
  • GF Score™: 59/100 with 2 warning signs

No single metric tells the full story. See the STU:NB11 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vaxart Business Description

Other Exchanges VXRT:USA
Address 170 Harbor Way, Suite 300, South San Francisco, CA, USA, 94080
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines based on its Vector Adjuvant Antigen Standardized Technology to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically, all the business activity functions through the region of the United States.
59GF Score

Get the complete analysis for STU:NB11

Inventories, Work In Process is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.60
Price
€8.37
GF Value